Structure
DCC-2036 Biochemical
DCC-2036
Purity
>98% (HPLC)
Synonyms
DCC-2036; Rebastinib; DCC 2036; DCC2036; DCC-2036 biochemical
Purity/Purification
>98% (HPLC)
Suitability
10mM in DMSO
Target
Bcr-Abl
Receptor
Abl1; FLT3; p-Abl1 (native); p-Abl1 (T315I); u-Abl1 (native)
Chemical Name
2-Pyridinecarboxamide, 4-[4-[[[[3-(1, 1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl
SMILES
O=C(NC1=CC=C(OC2=CC(C(NC)=O)=NC=C2)C=C1F)NC3=CC(C(C)(C)C)=NN3C4=CC=C5N=CC=CC5=C4
Molecular Formula
C30H28FN7O3
CAS Number
1020172-07-9
Preparation and Storage
Store at -20 degree C
Stability: >=2 years
Shipping: Ice Pack
Stability: >=2 years
Shipping: Ice Pack
Structure
Structure
Related Product Information for DCC-2036 biochemical
DCC-2036 (Rebastinib) is a highly potent, non-ATP-competitive BCR-ABL1 inhibitor with IC50 of 0.8 and 4nM for native ABL1 and gatekeeper mutant ABL1 T315I, respectively; also inhibits the SRC family kinases SRC, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2 (IC50s=2-40nM), but spares c-KIT (IC50=480nM); potently inhibits unphosphorylated and phosphorylated of ABL1 native with IC50 of 0.75 and 2nM, potently inhibits unphosphorylated and phosphorylated of ABL1 T315I with IC50 of 5 and 4nM, also potently inhibits ABL1 H396P (IC50=1.4nM); inhibits cellular proliferation of Ba/F3 cells expressing native or T315I mutant with IC50 of 5.4 and 13nM, also inhibits proliferation of several common TKI-resistant mutants of BCR-ABL1, including G250E, Q252H, Y235F, E255K, V299L, F317L, and M351T with IC50 of 6-150nM; prolongs survival in mouse Ba/F3 cell allograft models. Blood Cancer Phase 2 Clinical
Product Categories/Family for DCC-2036 biochemical
References
1. Chan WW, et al. Cancer Cell. 2011 Apr 12; 19 (4):556-68.
2. Eide CA, et al. Cancer Res. 2011 May 1; 71 (9):3189-95.
3. O'Hare T, et al. Blood. 2011 Nov 10; 118 (19):5250-4.
4. O'Hare T, et al. Clin Cancer Res. 2011 Jan 15; 17 (2):212-21.
2. Eide CA, et al. Cancer Res. 2011 May 1; 71 (9):3189-95.
3. O'Hare T, et al. Blood. 2011 Nov 10; 118 (19):5250-4.
4. O'Hare T, et al. Clin Cancer Res. 2011 Jan 15; 17 (2):212-21.
Similar Products
Product Notes
The DCC-2036 (Catalog #AAA3600095) is a Biochemical and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "DCC-2036, Biochemical" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
